Abstract
Although fluoxetine is useful in the treatment of major depression, 30–40 % of the patients do not respond to therapy. The
response seems to be influenced by certain genes which are involved in the drug’s pharmacodynamics and pharmacokinetics. The
present study reviews the literature on genetic contributions to fluoxetine response in children and adults, and concludes
that the different polymorphisms of CYP2D6 and CYP2C9 may influence the blood concentrations of fluoxetine. If the childhood
dose is adjusted for weight, differences between children and adults are unlikely. As regards the genes that influence the
drug’s pharmacodynamics, polymorphisms of SLC6A4, HTR1A and MAO-A seem to be involved in the response to fluoxetine, while
the genes COMT, CRHR1, PDEA1, PDEA11 GSK3B and serpin-1 also seem to play a role. Comparison of different studies reveals
that the results are not always consistent, probably due to methodological differences. Other factors such as gender or ethnicity
may also influence treatment response.
response seems to be influenced by certain genes which are involved in the drug’s pharmacodynamics and pharmacokinetics. The
present study reviews the literature on genetic contributions to fluoxetine response in children and adults, and concludes
that the different polymorphisms of CYP2D6 and CYP2C9 may influence the blood concentrations of fluoxetine. If the childhood
dose is adjusted for weight, differences between children and adults are unlikely. As regards the genes that influence the
drug’s pharmacodynamics, polymorphisms of SLC6A4, HTR1A and MAO-A seem to be involved in the response to fluoxetine, while
the genes COMT, CRHR1, PDEA1, PDEA11 GSK3B and serpin-1 also seem to play a role. Comparison of different studies reveals
that the results are not always consistent, probably due to methodological differences. Other factors such as gender or ethnicity
may also influence treatment response.
- Content Type Journal Article
- Category Review
- Pages 1-12
- DOI 10.1007/s00787-012-0305-6
- Authors
- Ana Blazquez, Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- Sergi Mas, Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
- Ma Teresa Plana, Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- Amàlia Lafuente, Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
- Luisa Lázaro, Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- Journal European Child & Adolescent Psychiatry
- Online ISSN 1435-165X
- Print ISSN 1018-8827